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Since 1981, the properties and physiological effects of human atrial natriuretic peptide (h-ANP) have been widely investigated, and its main natriuretic and vasodilative effects have been established
(1). However, there is still controversy as to whether the concentrations of h-ANP in plasma indicate a primary pathophysiological role for this peptide in the development of hypertension (2, 3) . Moreover, numerous different radioimmunoassays of plasma extracts have yielded various different values for the normal and pathophysiological ranges (1), indicating great methodological variability. To improve clinical practicability, investigators have tried to develop assays requiring no prior extraction (4) . However, results for direct assays and those involving extraction correlated satsifactorily only in the higher pathophysiological range of concentrations, thus not allowing discrimination between healthy and diseased subjects (5) . Some have doubted the reliability of direct assay (6) or have considered it too insensitive for clinical use (7, 8) .
Therefore, we have used a commercially available direct assay kit for h-ANP to examine samples from different individuals, to assess its reliability for clinical use. To overcome the problems of increasing pathophysiological variations, we characterize the different patient groups in detail, in terms of their diagnosis and ventricular function.
MaterIals and Methods

Plasma Samples
A 4-mL specimen of blood was drawn into pre-chilled (with ice-cold water) evacuated tubes coated with dipotassium EDTA and, without delay, 0.1 mL (2000 kallekrein inhibition units) of aprotinin solution was added, and the samples were chilled in ice-cold water. Within 15 to 30 miii the samples were centrifuged (30 mm, 4 #{176}C, 1700 x g). The plasma so obtained was divided into aliquots and frozen at -20 #{176}C until assay.
Direct Radioimmunoassay of h-ANP
To measure the concentrations of ANP in plasma, we used a commercially available radioimxnunoassay kit (Eiken Chemical Company Ltd., 33-8, Hongo 1-chome, Bunkyo-Ku, Tokyo, Japan) exactly as supplied. The kit contained rabbit antiserum to h-ANP, 1281-labeled h-ANP; goat antiserum to rabbit IgG (second antibody); phosphate buffer (no detailed specification available); and alpha-h-ANP
(1-28), 1280 ng/L, as standard. This standard was further diluted serially with the phosphate buffer to yield working standards having concentrations ranging from 20 to 640 ng/L. The direct assay procedure (i.e., involving no sample extraction) was performed exactly as proposed by the manufacturer. The h-ANP concentration in the plasma samples was determined from the standard curve, which was prepared by using the values obtained from the serial dilutions of the standard (Figure 1) .
For better characterization of the assay we also obtained a standard curve by serially diluting the supplied standard with h-ANP-free plasma prepared by extraction on Sep-Pak C-is cartridges (9) . Two plasma samples were serially diluted and assayed, to assess the linearity of the relation between results and sample concentration.
We attempted to compare results by this direct assay with those by a well-known extraction assay described by Hartter eta!. (9) for 30 plasma samples drawn from normal subjects, patients with coronary artery disease or cardiomyopathy, or patients who had undergone orthotopic heart transplantation. We also examined the correlation between the directly assessedh-AN? concentrations and the concentrations after prior extraction (9) by use of antibody supplied by Eiken Chemical Company. Samples were analyzed in duplicate by each method and the mean h-AN? concentration in plasma was only used if the 95% confidence ranges of each value overlapped; otherwise, the sample was excluded from further interpretation in this study. Therefore fewer than 30 identical samples were correlated for comparison of different methods, as indicated in the Results section.
The direct and extraction assays were done by two different and independent laboratories. Inter-laboratory correlation was assessedfor the direct assay. The two laboratories were not informed as to sample donors' health status or ventricular function.
Patients
The patients and controls (mean age 43, SD 15 y), all on a diet with salt unrestricted, were supine for 20 mm before blood sampling. All patients were monitored for heart rate and blood pressure during the sampling. Simultaneously, precise scintigraphic assessment of left-and right-ventricular function allowed calculation of left-(LVEF) and rightventricular ejection fraction, as described elsewhere (10).
Significant valvular regurgitation was excluded in these subjects by evaluation of the regurgitant index (11).
Apparently healthy individuals, volunteers
in an exercise-training program, were used as the normal controls to establish normal patterns for two-dimensional and Doppler echocardiography.
Because the laws in our country forbid assessment of healthy individuals by scintigraphy, their normal echocardiographic heart function was assumed to represent a normal LVEF (mean 65%).
We investigated plasma h-ANP concentrations and ventricular function in 35 patients with the following diagnoses: definite coronary artery disease (17), cardiomyopathy (three), orthotopic heart transplantation (eight), and unexplained cardiac symptoms (seven).
Statistical Analysis
All data are expressed as mean ± SD; if appropriate, the range and median value are also provided.
The minimum h-ANP concentration clearly distinguishable from zero was established by using Student's paired ttest, as applied by others (13 
Results
Radioimmunoassay Figure 1 shows the characteristic shape of the standard curve for the radioimmunoassay without prior extraction.
Half maximal displacement was 176 ± 13 ngfL. The sensitivity (detection limit) of the method was 20 ng/L at 95% and 40 ng/L at 99.9% confidence (paired t-test, n = nine assays of zero standards). Evaluation of the inter-assay variability for seven consecutive assays of h-ANP concentrations of 154 ± 8.2 and 41 ± 6.6 ng/L yielded CVs of 5.3% and 16%, respectively, indicating a sufficiently reproducible method. Inter-laboratory correlation was excellent (r = 0.985, SEE = 19 ngfL, n = 17).
No difference was seen between a dilution of pure standard prepared with h-ANP-free plasma and one prepared with buffer (Figure 1) .
The inset in Figure 1 shows that two patients' plasma samples with different supranormal h-ANP concentrations behaved similarly when further diluted by buffer.
Comparison of the direct assay with the assay after extraction yielded slightly contrasting results, depending on the antibody used. Figure 2a demonstrates that correlation with a previously validated method (9), performed by its developer, exhibited slight nonlinearity, as shown by polynomial fitting, whereas application of the same antibody as used in the direct assay to an otherwise identical extraction method developed by the same laboratory yielded excellent linear agreement, particularly in the critical low range of h-AN? concentrations in plasma (Figure 2b ). These results indicate a problem with the reference method's antibody sensitivity rather than with the specificity of the antibody used for the direct assay. This is discussed later also in the light of clinical aspects. For samples from 13 healthy volunteers (mean age 30, SD 13 y) with defined normal ventricular function, plasma h-ANP concentrations ranged up to 54 ngfL (median 33, mean 29, SD 15). These values were compared with two differently diseased patient groups: eight patients after orthotopic heart transplantation (h-ANP: 184 ± 65 ngIL) and a subgroup of six patients with coronary artery disease also characterized by normal resting LVEF (h-AN?: 93 ±29 ng/ L). All three groups differed significantly from one another by both parametric and nonparametric tests (F-ratio = 36.6 and Chi-square = 20.1, respectively,P <0.0001). Distinctive mean values and ranges are shown in Figure 3 . It can be seen that h-ANP concentrations may vary significantly between patient groups with different diagnoses but with normal ventricular function. When h-ANP concentrations in plasma were compared with LVEF (right ventricular function was normal in all patient groups) by regression analysis, a significant linear negative correlation (r = -0.64, P <0.001) between LVEF and plasma h-AN? concentrations was found after exclusion of patients in whom causes other than ventricular dysfunction could be contributing to increased h-AN? values (Figure 4b) .
In the remaining, less-well-defined patients with nonspecific cardiac symptoms or hypertension, and in patients after heart transplantation, there was no correlation at all (r = 0.02) between increased plasma h-AN? concentration and ventricular function ( Figure 4a )-for reasons that are explained in the Discussion.
Discussion
Except for one other report (13), this study is the first in which the direct radioimmunoassay described above has been used systematically for clinical evaluation. Plasma samples were collected by clinicians who did not rely only upon clinical symptoms and diagnosis, but also assessedleft and right ventricular function noninvasively and carefully supervised the plasma-collecting procedure. Because the plasma samples were subsequently assayed blind and in random order by two independent institutions whose main interest was the proper evaluation of the assay method itself; the results are likely to represent objective information about the assay's methodological reliability as well as its potential usefulness in clinical practice.
Because no information about the exact composition of the
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Evidently the kit will be particularly suitable for interinstitutional comparisons of clinical results, as indicated by the excellent correlation obtained for this method between the two cooperating radioimmunoassay laboratories.
However, a detection limit of 20 ng/L at 95% confidence was found, indicating less sensitivity than for the direct assay described by Marumo et al. (4) . Nevertheless, the present method proved to be twice as sensitive as the direct method used by Juppner et al. (7) . The slightly higher coefficient of variation, 16% in the low normal range, was still acceptable, revealing h-ANP concentrations in plasma of normal controls similar to the normal values obtained with the highly sensitive direct assay described by Marumo et al. (4) and by others using specially developed indirect assays (5, 9, 12). We attribute this to the high specificity of the h-ANP antibody used, which leads to practically identical plasma h-AN? concentrations, unaffected by prior extraction, as shown in Figure 2b . These results were obtained by a laboratory that uses pre-analysis extraction of the sample and is known for its accuracy in h-ANP assessment, on the basis of an international collaborative study (14) . However, when the same method was applied by the same laboratory using an accepted antibody as a reference to compare and establish compatibility with the direct assay, a slight nonlinearity was found, as demonstrated best by a polynomial fit in Figure 2a (15) , who, using a different h-ANP antibody, reported consistently higher h-AN? concentrations in plasma when such extraction was not performed. Therefore, the discrepancy between the direct and indirect (extraction) methods might be caused by different or changing sensitivity and (or) specificity of the antibody. However, when the antibody of the commercially available assay kit we tested was used, with or without prior extraction, no discrepancies could be found, as seen in Figure 2b . This suggests that the antibody is of adequate sensitivity and specificity, but this may apply only if aprotinin is added immediately after the sampling procedure to block the mechanism that leads to a nonspecific immunoreactivity, as discussed elsewhere (9), and if the plasma is thoroughly centrifuged to eliminate the adverse effect of platelet contamination of plasma used in the direct assay, as has already been established (12). Nevertheless, this source of error was not eliminated in other important comparative studies of direct and extracted assays (12, 15). Our direct assay of plasma rendered platelet-free seemed insensitive to nonspecific immunoreactive components, which are thought to interfere with other direct assay methods, as described by Richards et al. (12) . We attribute this to the apparently high specificity of the antibody used. Additional clinical data from the patient cohort investigated throw further light on the possibility of a higher sensitivity for this antibody. This is best demonstrated in two patients, indicated by the arrow in Figure 2a , for whom the direct assay yielded values in the pathological range, about three times higher than the values for plasma h-ANP concentration assessedin identical samples by the comparison method, which yielded values that clearly were within the normal range. Even after extraction, no such discrepancy existed with the antibody we tested. Even though some concentrations were outside the normal range, they appeared reasonable because the corresponding patients had documented myocardial infarction and slight congestive heart failure, respectively.
This new assay could just barely distinguish between plasma h-AN? with a highly sensitive direct assay, and also with those evaluated after extraction (9,12). However, they disagreed with the three-times-higher upper normal limit assessed by JUppner et al. (7), who would appear to have used a less-specific and less-sensitive direct method.
Besides the specificity of the assay method, another explanation for the low upper limit of the h-AN? plasma concentrations in the control subjects might be that all controls were not merely apparently healthy, but had also been found normal in two-dimensional and Doppler echocardiography.
However, one clinically healthy sportsman (30 years old) was excluded from the control group because of slight valvular regurgitation owing to a mitral valve prolapse. He also had an above-normal value for h-ANP, 90 ng/ L (16). These precautions might not have been considered by authors using another direct method (3, 7), which has been criticized (8).
Comparison of defined groups with normal left and right ventricular function demonstrated for the first time that a freely available direct assay clearly discriminates between completely healthy individuals and patients with various underlying pathological conditions (discussed below). Although the healthy control group was significantly younger than the patients, the differences in h-AN? concentrations far exceeded the minimal difference attributable to age (12). Patients having coronary artery disease with normal LVEF (normal systolic function) and patients with hypertension often suffer from ventricular diastolic filling abnormalities (17, 18) that result in slightly increased heartchamber pressures and tensions, a cause of increased h-AN? secretion (19, 20) . The assumption is further supported by recent reports about the localization of atrial natriuretic peptide immunoreactivity in the ventricular myocardium as well (21) . Thus, in hypertensive patientswith preserved systolic function (normal LVEF), hypertrophy of the left ventricle is ascribable to increasing myocardial mass, and this, mediated by the sympathetic stimulus of elevated myocardial wall stress, leads to increased production of h-AN? (22) .
In patients who have had a myocardial infarction, increased ventricular h-AN? mRNA has been detected in infarcted as well as non-infarcted ventricles. Both hemodynamic and metabolicchanges are thought to trigger the expression of the AN? gene (23), which precedes increased h-AN? production, and this might also explain the increased plasma h-AN? concentrations in patients with coronary artery disease when systolic function (LVEF) is still normal.
In patients who have undergone orthotopic heart transplantation, markedly increased h-AN? concentrations were found despite normal systolic ventricular function. Here, the changes in the electrolyte and fluid balance caused by corticosteroid intake (24) and the influence of other immunosuppressive drugs are thought to be the mechanism responsible for increased h-ASP secretion (25).
In our opinion, the groups of patients investigated here, with different underlying causes for h-AN? elevation, have adequately demonstrated the possible clinical relevance of the assay we tested in patients with normal systolicventric-
as assessed by left ventricular ejection fraction. However, with primary extracardiac causes of increased h-AN? production excluded, and for patients with defined presence or absence of cardiac disease, this study is the first to reveal a clear correlation between left ventricular dysfunction and elevated h-AN? as assessed by a direct assay (Figure 4b) . Although no patientwas symptomatic at the time of investigation, increased h-AN? production might alsoreflect increased pressures in the left ventricle and atrium (26, 27). However, in patientswith less welldefined symptoms-comprising those with heart neuroses, mitral valve prolapse, hypertension, and unconfirmed coronary artery disease or orthostatic disorders of circulating volume regulation-ventricular function did not show any correlation (Figure 4a ) with normal or above-normal plasma h-ANP concentrations, which might have been caused by cardiac or non-cardiac causes as discussed above. This study shows that both cardiac and non-cardiac causes may influence h-ANP concentrations, which can be reliably measured by the present direct assay. Nevertheless, it must be stressed that, even if an accurate assay is used, evident clinical symptoms or diagnoses alone are an insufficient basis for unequivocal interpretation of increased h-ANP concentrations. Thus, noninvasive testing of ventricular function usefully supplements the proper interpretation of h-AN? concentrations in apparently healthy individuals or patients.
We conclude that this direct assay of h-ANP in plasma yields clinically valuable information, which could be used to help evaluate heart disorders and other pathophysiological conditions causing increased plasma h-AN? concentrations. However, further extensive investigation of h-AN? concentrations in humans seems necessary for better understanding of its pathophysiological relevance. Such studies might be facilitated in practice by the availability of a sufficiently accurate direct assay method for h-ANP, as presented.
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